This page features ACC's full coverage of the latest science from Transcatheter Cardiovascular Therapeutics (TCT) 2023 – including trial summaries, news stories, journal scans, videos and more.
Dec 12, 2024 | Anthony A. Bavry, MD,MPH,FACC
The goal of the TRILUMINATE Pivotal trial was to evaluate percutaneous tricuspid valve transcatheter edge-to-edge repair (TEER) compared with medical therapy among patients with symptomatic severe tricuspid regurgitation.
Oct 30, 2024 | Dharam J. Kumbhani, MD, SM, FACC
The goal of the CLASP IID trial was to assess the safety and efficacy of the PASCAL system compared with the MitraClip among patients with degenerative mitral regurgitation (MR) who were at prohibitive surgical risk.
Oct 09, 2024 | Muhammad Asim Shabbir, MD; Poonam Velagapudi, MD, MS, FACC
Renal denervation (RDN) is an adjunct treatment for hypertension (HTN) that involves catheter ablation of the sympathetic plexus in the adventitia of the renal arteries using radiofrequency (RF) or ultrasound waves.
Mar 20, 2024 | Dharam J. Kumbhani, MD, SM, FACC
The goal of the AGENT IDE trial was to assess the safety and efficacy of a paclitaxel-coated balloon (drug-coated balloon; DCB) to conventional balloon angioplasty among patients with coronary in-stent restenosis (ISR).
Jan 04, 2024 | Anthony A. Bavry, MD,MPH,FACC
The goal of the LIFE-BTK trial was to evaluate the use of an everolimus-eluting resorbable scaffold compared with balloon angioplasty among patients with chronic limb-threatening ischemia and infrapopliteal artery disease.
Dec 01, 2023
Here's a lightening round of takeaways from a few coronary and structural trials presented during TCT 2023 that bring us new insights to consider for refining clinical practice.
Nov 27, 2023 | Anthony A. Bavry, MD,MPH,FACC
The goal of the PARTNER 3 trial was to evaluate transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR) among low-risk patients with symptomatic severe aortic stenosis.
Nov 15, 2023 | Daniel J Snyder, MD; Sanjum S Sethi, MD, FACC
As Transcatheter Cardiovascular Therapeutics (TCT) 2023 has come to a close, it is time to review some of the most impactful studies that were shared at the conference. In the peripheral artery disease (PAD) space, results of the LIFE-BTK (pivotaL...
Nov 02, 2023 | Anthony A. Bavry, MD,MPH,FACC
The goal of the BIOSTEMI trial was to evaluate biodegradable polymer sirolimus-eluting stents compared with durable polymer everolimus-eluting stents among patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment-elevati...
Oct 26, 2023 | Ajay J. Kirtane, MD, FACC; Dharam J. Kumbhani, MD, SM, FACC; Ki Park, MD, FACC
Drs. Dharam Kumbhani, Ki Park, and Ajay Kirtane review the late-breaking clinical trials from Thursday, October 26 at TCT 2023 including RADIANCE (0:44) and TRILUMINATE (3:32).
Oct 26, 2023 | Ajay J. Kirtane, MD, FACC; Dharam J. Kumbhani, MD, SM, FACC; Ki Park, MD, FACC
Drs. Dharam Kumbhani, Ki Park, and Ajay Kirtane review the late-breaking clinical trials from Thursday, October 26 at TCT 2023 including RADIANCE (0:44) and TRILUMINATE (3:32).
Oct 26, 2023
Development of new left bundle branch block (LBBB) following TAVR may be associated with an increased risk of mortality and hospital readmission as well as worse health status and lower left ventricular ejection fraction (LVEF), according to...
Oct 26, 2023
Compared with plain balloons, drug-coated balloons (DCB) and, particularly, drug-eluting stents (DES) are able to reduce the need of both first and recurrent revascularizations after percutaneous treatment of drug-eluting in-stent restenosis...
Oct 26, 2023
Results from the CLASP IID trial full cohort, presented Oct. 26 during TCT 2023 and simultaneously published in JACC: Cardiovascular Interventions, demonstrated noninferiority of mitral valve transcatheter edge-to-edge repair (M-TEER) using the...
Oct 26, 2023
Results from the VIVA trial comparing hemodynamic and clinical outcomes between TAVR and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis (AS) and small aortic annulus (SAA) provide important insights into how best...
Oct 26, 2023 | Dharam J. Kumbhani, MD, SM, FACC
The optimal treatment of drug-eluting stent (DES) in-stent restenosis (ISR) is not well established. The ISAR-DESIRE 3 trial sought to compare three different strategies for the treatment of DES ISR: 1) treatment with paclitaxel-eluting balloon...
Oct 26, 2023 | Dharam J. Kumbhani, MD, SM, FACC
The goal of the RADIANCE-HTN SOLO trial was to assess the safety and efficacy of renal denervation compared with sham control among patients with mild to moderate systolic and diastolic hypertension.
Oct 26, 2023 | Dharam J. Kumbhani, MD, SM, FACC
The goal of the RADIANCE II trial was to assess the safety and efficacy of renal denervation compared with sham control among patients with stage II hypertension (HTN).
Oct 26, 2023
Results from two separate late-breaking clinical trials presented Oct. 26 during TCT 2023 – TRILUMINATE Pivotal and TRISCEND II – add to the growing body of evidence surrounding tricuspid valve repair in patients with severe tricuspid regurgitatio...
Oct 25, 2023 | Ajay J. Kirtane, MD, FACC; Dharam J. Kumbhani, MD, SM, FACC; Ki Park, MD, FACC
Drs. Dharam Kumbhani, Ki Park, and Ajay Kirtane review the late-breaking clinical trials from Wednesday, Oct. 25 at TCT 2023, including AGENT IDE (0:45), T-PASS (3:44), and SWEDEHEART (6:50).
Log in to MyACC